Cognition Therapeutics, Inc. (CGTX)
$0.80-6.98%Close
SELLCRISIS · day 9
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $72M
- Beta
- 1.80
- P/E (TTM)
- -4.18
- Short % float
- 9.27%
- Days to cover
- 16.6
- SI change
- -2.1%
- 1W
- -14.89%
- 1M
- -20.79%
- vs SPY 1W
- -14.75%
- vs SPY 1M
- -23.30%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 12
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-30.1%
REV YoY-
ROE-50.2%
EPS YoY-
ROA-43.1%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-4.18
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.20
P/FCF-
EV/EBITDA-2.32
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.55
ALTMAN Z-
CURR RATIO7.03
ND/EBITDA-
BETA1.80
Company news
FAQ
- What is LOPJLB’s current signal on CGTX?
- LOPJLB’s latest quantitative signal on Cognition Therapeutics, Inc. (CGTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CGTX in?
- Cognition Therapeutics, Inc. (CGTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Cognition Therapeutics, Inc. (CGTX) do?
- Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a …